OncoSec Medical Incorporated
Simbols: ONCS
NASDAQ
0.2772
USDTirgus cena šodien
-0.0457
P/E koeficients
-0.0010
PEG koeficients
1.65M
MRK Cap
- 0.00%
DIV ienesīgums
OncoSec Medical Incorporated (ONCS) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 41.19 | 12.3 | 46 | 20.4 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.other-current-assets | 10.25 | 2.9 | 3.2 | 2.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 51.44 | 15.2 | 49.2 | 22.8 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 17.97 | 5.6 | 6.4 | 6.8 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 1.48 | 0.4 | 0.4 | 0 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1.48 | 0.4 | 0.4 | 0 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 2.29 | 0.6 | 0.3 | 0.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 21.74 | 6.6 | 7.1 | 7.1 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 73.18 | 21.9 | 56.3 | 29.9 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.short-term-debt | 6.22 | 2 | 2.1 | 1.5 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 14.19 | 4.1 | 5.2 | 6.4 | |||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 19.24 | 4.6 | 5.9 | 8.2 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 34.19 | 9.1 | 10.2 | 6.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 16.39 | 5.2 | 6.1 | 6.4 | |||||||||||||||
balance-sheet.row.total-liab | 59.65 | 15.8 | 18.2 | 16 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0.01 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.retained-earnings | -1158.6 | -286 | -251.8 | -206.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1.48 | 0.2 | -0.1 | 0 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1170.65 | 291.8 | 289.9 | 220.5 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 13.54 | 6.1 | 38.1 | 13.9 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 73.18 | 21.9 | 56.3 | 29.9 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-equity | 13.54 | 6.1 | 38.1 | 13.9 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 73.18 | - | - | - | |||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-debt | 20.41 | 6.2 | 7.3 | 7.8 | |||||||||||||||
balance-sheet.row.net-debt | -20.78 | -6.1 | -38.6 | -12.5 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -29.39 | -34.2 | -45.2 | -42.3 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.94 | 1.1 | 1.1 | 1 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -0.8 | -0.1 | |||||||||||||||
cash-flows.row.stock-based-compensation | 1.28 | 1.6 | 5.1 | 3.5 | |||||||||||||||
cash-flows.row.change-in-working-capital | 2.05 | -1.2 | -2.5 | 3.8 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.account-payables | -1.38 | -1.4 | -2.6 | 3.6 | |||||||||||||||
cash-flows.row.other-working-capital | 3.43 | 0.2 | 0.1 | 0.2 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0.12 | 0.6 | 0.5 | 0.9 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -24.99 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.24 | -0.2 | -0.8 | 0 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.26 | -0.2 | -0.8 | 0 | |||||||||||||||
cash-flows.row.debt-repayment | -1.15 | -1.3 | -0.6 | -0.1 | |||||||||||||||
cash-flows.row.common-stock-issued | 0.04 | 0 | 62.8 | 30 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-financing-activites | 4.65 | 0.1 | 6 | -1.5 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 3.54 | -1.2 | 68.2 | 28.4 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.08 | -0.1 | 0 | 0 | |||||||||||||||
cash-flows.row.net-change-in-cash | -21.55 | -33.7 | 25.6 | -4.8 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 41.19 | 12.3 | 46 | 20.4 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 62.74 | 46 | 20.4 | 25.1 | |||||||||||||||
cash-flows.row.operating-cash-flow | -24.99 | -32.1 | -41.8 | -33.1 | |||||||||||||||
cash-flows.row.capital-expenditure | -0.24 | -0.2 | -0.8 | 0 | |||||||||||||||
cash-flows.row.free-cash-flow | -25.24 | -32.4 | -42.6 | -33.1 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 21.77 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 10.88 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.06 | 0 | 0 | 0.2 | |||||||||||||||
income-statement-row.row.operating-expenses | 32.65 | 37 | 48.4 | 43.4 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 32.65 | 37 | 48.4 | 43.4 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.interest-expense | 0.05 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -0.07 | -0.5 | 0.8 | 0.3 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.06 | 0 | 0 | 0.2 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -0.07 | -0.5 | 0.8 | 0.3 | |||||||||||||||
income-statement-row.row.interest-expense | 0.05 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.99 | 1.1 | 1.1 | 1.2 | |||||||||||||||
income-statement-row.row.ebitda-caps | -31.66 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | -32.65 | -37 | -48.4 | -43.4 | |||||||||||||||
income-statement-row.row.income-before-tax | -32.72 | -37.5 | -47.6 | -43.1 | |||||||||||||||
income-statement-row.row.income-tax-expense | -2.58 | -3.3 | -2.4 | -0.9 | |||||||||||||||
income-statement-row.row.net-income | -30.14 | -34.2 | -45.2 | -42.3 |
Biežāk uzdotie jautājumi
Kas ir OncoSec Medical Incorporated (ONCS) kopējie aktīvi?
OncoSec Medical Incorporated (ONCS) kopējie aktīvi ir 21878368.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.000.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -4.923.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.000.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.000.
Kāda ir OncoSec Medical Incorporated (ONCS) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -34179634.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 6174765.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 37012062.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 3683330.000.